Member Info for Mikemine

We are at war with the Islamists and in wars stock prices rarely do well.

I reckon you're right B. If the red trades over the last week were actual sell trades I'm sure the MMs would have lowered the price. It's eased very slightly but it looks like there is support at these levels, and why not?

There must be some potential investors who keep an eye on these blogs and RNSs and don't post. I'm curious to know what they think and what stops them from investing and, what is more important I suppose, what would make them put their hand in their pocket. So, if any of these guys would care to post here I'd be very interested and grateful.

SB, you do realise that the podcasts etc have all ticked those boxes, obviously not to PIs satisfaction. My take is the PI's are mega adversed to fundraising and this over rides more or less any other consideration. Secondary, the slowness to break even, or even profit, is taking its toll.

My view on fund raising is pretty sanguine. You have to speculate to accumulate, thats true, and this is a whole lot different to fundraising just to keep the lights on. We've been told numerous times that the next fundraise, and it's pretty certain it must happen, will be overwhelmingly used to increase the sales force and marketing. To me that's positive. Sales are already increasing with existing staff so increasing the staff should multiply that.

You know, the worse thing about investing in these small companies with limited products is the gaps between news. VRCI is no exception and the gaps leave investors feeling isolated and fearful. It will be good when there is something to report again.

One of the best analysis I've seen. It lists pro's and con's of which followers here will well aware. Basically they are saying the company has no debt, has enough cash for the time being, has revenue increasing and has contracts and agreements, such as Blue Cross, in place to add access and credibility. On the negative side it is loss making and is at risk of not selling enough by low acceptance, which is not what we are seeing I would suggest.

This is not without risk but with an increase in sales force that could address the larger market now open to it, I reckon revenue could mushroom. To get a larger sales force however will need more money but that's the name of the game with tiny companies.

It worth reading the link that 2Phones provided and post your reading of it here.

If they fundraise at anywhere near 0.25p I'll be filling up and probably double my holding. Personally I can't see it happening but AIM is a ridiculous market so who knows.

Can you read Sandyman or just have trouble understanding what is written?

We are due an AGM around the end of May, I believe, and final result came out in June last year. That gives VRCI a bit of time to show acceleration in sales if they have any. Judging by talks and videos we have seen, acceleration is definitely on the cards. With an increase in sales force it could hardly be otherwise. Apart from that I would expect an increase in regular use and maybe more interest from other organisations. In other words Tutivia might be becoming mainstream. It would be nice to hear how Calvara is progressing although VRCI have little influence over that. Not much happening at the moment.

SP holding up well considering the political situation and the global sell off but VRCI is probably well under the radar of Goldman Sachs etc. I hope the Iranian people get freedom though.

What large buy?

I don't suppose this will do anybody's SP any good. Didn't expect it for a few days.

I think thats realistic Lordmakealot.

Getting to just breakeven would do wonders for the SP. Of course it's not a done deal and it could all go wrong but, to me, it all looks good right now.

Just an opinion so don't take anything as a share tip or advice. No offence taken SB. i thought it was funny actually.

Be fair SB. VRCI is well undervalued and the initial market they are going for is $300 mn. In 5 years they should have captured a big slice of that so turnover of $250 mn is not unreasonable i would have thought. Believe it or not they are a re quick moving company, relative to their funding restrictions. so a speedy advance on the sales front, now all the testing and approvals are in place, is not unreasonable. 5 years is a long time in business.

It's all speculation anyway as I reckon they will be taken out within 18 months or so once the sales are flowing in a bigger way.

It may seem that I am just a ramper with an ulterior motive but I'm just very enthusiastic about this one.

I wouldn't be venturing these opinions had not Lordmakealot asked for it so I thought I'd chip in. What would your reply be to his question?

If it's around in 5 years I'd say a £500mn valuation but more realistically it will be bought before then. Just my opinion.

here's the link. sales and marketing are firm priorities. should tweet the interest of pis not already invested, especially at these valuations.

https://www.***************************/verici-dx-drives-commercial-growth-capturing-us-transplant-market-lonvrci/4121240437#:~:text=verici%20dx%20plc%20(lon%3avrci)%20chief,of%20its%20flagship%20test%2c%20tutivia.

I've rarely seen an opportunity like this. It's still a risk but the sales momentum tells the story. It's getting really well accepted by insurance companies etc along with a growing band of clinicians. Dilution is always an issue with tiny companies and I can only assume that is putting PIs off but the potential SP multiples will overcome that I reckon. TBH, at this late stage, I can't understand anybody selling when VRCI is on the cusp of a really good year.

Anyway, good luck with you million.

good summary. nothing we've not been told before but this clarifies the commercialisation business model which is bearing fruit increasingly.

"the increase in revenue reflects higher test volumes as transplant centres integrate tutivia more consistently into patient monitoring protocols. the company’s strategy has centred on demonstrating clinical utility and then converting that validation into routine usage."

https://www.***************************/verici-dx-revenue-growth-signals-commercial-inflection-point/4121239566

it's the "routine usage" that will lead the way to profit imho.

can't wait for the next commercial update which i'm hoping will show an accelerating rate of uptake.

As far as I know, it's sold to individual clinicians but first RENX aims to secure the test within a hospital's protocol for dealing with transplants. The clinician is approached by a salesperson and then it's up to the clinician to order the test. The tests are not sold in bulk as the testing outcomes are determined back in RENX's lab individually. The test also has to be approved by the payer, either Medicare or an insurance company, which has occupied RENX quite a bit to arrange this. I'd imagine there are very few private patients willing or able to pay for the test directly, via their clinician of course. Once the clinician is on board with the first test, I'd imagine they would be left alone to order more tests although the salesperson would probable return to get a feedback and sort out any problems. This process would involve quite a lot of meetings, conference attendances and presentations to groups. Medical clinicians are notoriously conservative in their approach to new innovations, quite rightly I reckon, so it's always a hard and lengthy slog to succeed in this field and it proving that way with RENX. RENX have done a lot of background work and now, as the test is proven and authorised, they are in the commercialisation stage. It's proving much slower than we or the BOD would like I'm sure but these things have a momentum of their own and usually reach a critical point when the product takes off. It looks like RENX hasn't reached that point yet but the test has being sold and there is re-ordering. The risk is that RENX won't reach the tipping point so we have to make our own minds about that.

As I said, "as far as i know", so I may be well out so I'd invite anybody else to correct me. I'm not an advisor so don't treat this post as financial advice. It's just an opinion.

Interesting take Stocky. Personally I like her style as it feels like she is talking on a one to one basis. She obviously doesn't follow a script although she must have repeated the information loads of times to the interested. Yes, I agree it'll take longer than a few months to fulfil VRCI's potential and really get in to multi-bagger country but it won't happen all of a sudden and we will get encouraging and informative updates along the way which will be SP positive. Patience, as ever, is needed with these tiddlers.